Trial · NCT03155997
Adverse events848
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
221 to 240 of 848
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pneumonitis | Respiratory, thoracic and mediastinal disorders | 150 mg Abemaciclib + Endocrine Therapy | 36 | 2,791 | 36 |
| other | Pneumonitis | Respiratory, thoracic and mediastinal disorders | Endocrine Therapy | 10 | 2,800 | 10 |
| other | Productive cough | Respiratory, thoracic and mediastinal disorders | 150 mg Abemaciclib + Endocrine Therapy | 45 | 2,791 | 53 |
| other | Productive cough | Respiratory, thoracic and mediastinal disorders | Endocrine Therapy | 25 | 2,800 | 28 |
| other | Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | 150 mg Abemaciclib + Endocrine Therapy | 40 | 2,791 | 41 |
| other | Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | Endocrine Therapy | 40 | 2,800 | 42 |
| other | Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | 150 mg Abemaciclib + Endocrine Therapy | 29 | 2,791 | 31 |
| other | Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | Endocrine Therapy | 15 | 2,800 | 16 |
| other | Alopecia | Skin and subcutaneous tissue disorders | 150 mg Abemaciclib + Endocrine Therapy | 254 | 2,791 | 266 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Endocrine Therapy | 53 | 2,800 | 53 |
| other | Dermatitis | Skin and subcutaneous tissue disorders | 150 mg Abemaciclib + Endocrine Therapy | 28 | 2,791 | 31 |
| other | Dermatitis | Skin and subcutaneous tissue disorders | Endocrine Therapy | 11 | 2,800 | 13 |
| other | Dry skin | Skin and subcutaneous tissue disorders | 150 mg Abemaciclib + Endocrine Therapy | 102 | 2,791 | 108 |
| other | Dry skin | Skin and subcutaneous tissue disorders | Endocrine Therapy | 48 | 2,800 | 51 |
| other | Eczema | Skin and subcutaneous tissue disorders | 150 mg Abemaciclib + Endocrine Therapy | 29 | 2,791 | 32 |
| other | Eczema | Skin and subcutaneous tissue disorders | Endocrine Therapy | 28 | 2,800 | 31 |
| other | Erythema | Skin and subcutaneous tissue disorders | 150 mg Abemaciclib + Endocrine Therapy | 38 | 2,791 | 43 |
| other | Erythema | Skin and subcutaneous tissue disorders | Endocrine Therapy | 26 | 2,800 | 28 |
| other | Hyperhidrosis | Skin and subcutaneous tissue disorders | 150 mg Abemaciclib + Endocrine Therapy | 29 | 2,791 | 33 |
| other | Hyperhidrosis | Skin and subcutaneous tissue disorders | Endocrine Therapy | 32 | 2,800 | 34 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03155997/events?page=12